ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Amgen, Swedish Orphan Biovitrum and Hamad Medical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Amgen×Swedish Orphan Biovitrum×Hamad Medical×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AmgenSwedish Orphan BiovitrumHamad Medical
studies on the registry1,088137139
open to participants now50627
phase 3 studies under way5052
reach primary completion within a year3536
programswith a study of their own in two years2474

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAmgenSwedish Orphan BiovitrumHamad Medical
Phase 1

Amgen: 8 of its 24 programs at phase 1

  1. AMG 691phase 1
  2. AMG 127phase 1
  3. etakafusp alfaphase 1
  4. Pan-KRAS Inhibitor AMG 410phase 1
  5. tambotatug pelitecanphase 1

and 3 more — sign in to see them all

33%
00%

Hamad Medical: 1 of its 4 programs at phase 1

  1. Hydrophilic Methacrylate Gelno phase
25%
Phase 2

Amgen: 1 of its 24 programs at phase 2

  1. AMG 732phase 2
4%

Swedish Orphan Biovitrum: 1 of its 7 programs at phase 2

  1. XOI Low Dosephase 2
14%
00%
Phase 3

Amgen: 7 of its 24 programs at phase 3

  1. maridebart cafraglutidephase 3
  2. tarlatamabphase 3
  3. xaluritamigphase 3
  4. sotorasibphase 3
  5. olpasiranphase 3

and 2 more — sign in to see them all

29%

Swedish Orphan Biovitrum: 2 of its 7 programs at phase 3

  1. pacritinibphase 3
  2. AR882phase 3
29%
00%
Approved, new studies

Amgen: 8 of its 24 programs at approved, new studies

  1. inebilizumabapproved, new study
  2. blinatumomabapproved, new study
  3. apremilastapproved, new study
  4. evolocumabapproved, new study
  5. romiplostimapproved, new study

and 3 more — sign in to see them all

33%

Swedish Orphan Biovitrum: 4 of its 7 programs at approved, new studies

  1. efanesoctocog alfaapproved, new study
  2. pegcetacoplanapproved, new study
  3. avatrombopagapproved, new study
  4. Interleukin 1 Receptor Antagonist Proteinapproved, new study
57%

Hamad Medical: 3 of its 4 programs at approved, new studies

  1. Antioxidantsapproved, new study
  2. Clomipheneapproved, new study
  3. Follicle Stimulating Hormoneapproved, new study
75%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Amgen12 readouts · 3 phase 3·

Amgen, Dec ’26: 1 program whose next study reaches primary completion

  1. sotorasibphase 3 · Dec 17 · NCT04185883

Amgen, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. AMG 732phase 2 · Jan 6 · NCT06401044
  2. apremilastapproved, new study · Jan 10 · NCT07908641
  3. romosozumabapproved, new study · Jan 14 · NCT07811999
  4. maridebart cafraglutidephase 3 · Jan 21 · NCT06858839

Amgen, Feb ’27: 1 program whose next study reaches primary completion

  1. xaluritamigphase 3 · Feb 17 · NCT06613100

Amgen, Mar ’27: 1 program whose next study reaches primary completion

  1. AMG 691phase 1 · Mar 17 · NCT07745907

Amgen, Apr ’27: 2 programs whose next study reaches primary completion

  1. inebilizumabapproved, new study · Apr 13 · NCT05549258
  2. tarlatamabphase 3 · Apr 24 · NCT06598306

Amgen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. evolocumabapproved, new study · May 29 · NCT05284747
·

Amgen, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. afliberceptphase 3 · Jul 31 · NCT07614776
··

Amgen, Oct ’27: 1 program whose next study reaches primary completion

  1. AMG 127phase 1 · Oct 2 · NCT07590193
Swedish Orphan Biovitrum3 readouts · 1 phase 3

Swedish Orphan Biovitrum, Nov ’26: 2 programs whose next study reaches primary completion

  1. AR882phase 3 · Nov 0 · NCT07116746
  2. XOI Low Dosephase 2 · Nov 0 · NCT07116746
···

Swedish Orphan Biovitrum, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Mar 0 · NCT06716814
·······
Hamad Medical3 readouts · 3 phase 3···········

Hamad Medical, Oct ’27: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. Antioxidantsapproved, new study · Oct 15 · NCT07862725
  2. Clomipheneapproved, new study · Oct 15 · NCT07862725
  3. Follicle Stimulating Hormoneapproved, new study · Oct 15 · NCT07862725
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 24, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Amgen

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 5

Swedish Orphan Biovitrum

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Hamad Medical

New programs 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 7 in all. A program counts in each condition its studies name most.

ConditionAmgenSwedish Orphan BiovitrumHamad Medical
COVID-192 of 3 · compare here

Amgen in COVID-19: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of COVID-19 in search

Swedish Orphan Biovitrum in COVID-19: 2 programs

  1. pacritinibphase 3
  2. Interleukin 1 Receptor Antagonist Proteinapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of COVID-19 in search

–
Anemia, Aplastic2 of 3 · compare here

Amgen in Anemia, Aplastic: 1 program

  1. romiplostimapproved, new study

Their studies: Amgen’s studies of Anemia, Aplastic in search

Swedish Orphan Biovitrum in Anemia, Aplastic: 1 program

  1. avatrombopagapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of Anemia, Aplastic in search

–
Arthritis, Juvenile2 of 3 · compare here

Amgen in Arthritis, Juvenile: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of Arthritis, Juvenile in search

Swedish Orphan Biovitrum in Arthritis, Juvenile: 1 program

  1. Interleukin 1 Receptor Antagonist Proteinapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of Arthritis, Juvenile in search

–
Arthritis, Rheumatoid2 of 3 · compare here

Amgen in Arthritis, Rheumatoid: 1 program

  1. dazodalibepphase 3

Their studies: Amgen’s studies of Arthritis, Rheumatoid in search

Swedish Orphan Biovitrum in Arthritis, Rheumatoid: 1 program

  1. Interleukin 1 Receptor Antagonist Proteinapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of Arthritis, Rheumatoid in search

–
Macular Degeneration2 of 3 · compare here

Amgen in Macular Degeneration: 1 program

  1. afliberceptphase 3

Their studies: Amgen’s studies of Macular Degeneration in search

Swedish Orphan Biovitrum in Macular Degeneration: 1 program

  1. pegcetacoplanapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of Macular Degeneration in search

–
Purpura, Thrombocytopenic, Idiopathic2 of 3 · compare here

Amgen in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. romiplostimapproved, new study

Their studies: Amgen’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Swedish Orphan Biovitrum in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. avatrombopagapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of Purpura, Thrombocytopenic, Idiopathic in search

–
Renal Insufficiency2 of 3 · compare here

Amgen in Renal Insufficiency: 1 program

  1. olpasiranphase 3

Their studies: Amgen’s studies of Renal Insufficiency in search

Swedish Orphan Biovitrum in Renal Insufficiency: 1 program

  1. AR882phase 3

Their studies: Swedish Orphan Biovitrum’s studies of Renal Insufficiency in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAmgenSwedish Orphan BiovitrumHamad Medical
MPLromiplostimruleavatrombopagrule–
A target, or a pathogen for a vaccine, known for: Amgen 17 of 24 · Swedish Orphan Biovitrum 5 of 7 · Hamad Medical 2 of 4 programs (23 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.